Synergistic Drug Development
The SynDevRx clinical program is robustly designed to increase the likelihood of success. As we advance our best-in-class lead compound* through the regulatory process, we expect to continue contributing to the fundamental understanding of cancer biology.
We are developing a pipeline of novel compounds that target MetAP2 in a formulation-dependent way. Our lead compound is currently undergoing pre-clinical studies.
Our clinical development team is comprised of highly experienced drug development professionals. We are efficiently moving our lead compound from pre-clinical testing to investigational new drug (IND) status and through human clinical trials.
The internal development group possesses expertise in the critical areas of clinical trial design and management, process development, chemistry, manufacturing and controls (CMC), toxicology, pharmacology, and regulatory affairs. We believe our adaptability, creativity, persistence and fiscal discipline distinguish us from other biotech companies. We expect to create a valuable pipeline of anti-angiogenic compounds that have the potential to positively impact the lives of patients and doctors.
*This compound/technology is not yet available for clinical use in either the US or anywhere else in the world.